T cell activation in COVID-19 was analyzed by the expression of HLA-DR, a subtype of the human leukocyte antigen class II, in the subpopulations of less differentiated CD56− and more differentiated CD56+ T cells. This evidence concerns the gene NCAM1 and COVID-19.